SeaStar Medical and AREVA Institute Collaborate on Innovative Burn Treatment Research with DoD Grant

Severe burns, inhalation injuries, and septicemia often lead to destructive hyperinflammation, complicating recovery and increasing mortality risks. A new research study, supported by a Department of Defense (DoD) grant, seeks to address these challenges through innovative therapy. The study will explore the use of SeaStar Medical's Selective Cytopheretic Device (SCD) therapy, designed to neutralize hyperinflammation and improve patient outcomes.

The Autonomous Reanimation and Evacuation (AREVA) Research Institute received the grant as part of the 2024 Military Burn Research Program (MBRP), highlighting the potential of SCD therapy in treating combat casualties and civilian patients alike. The therapy, used alongside continuous renal replacement therapy (CRRT), aims to support organ recovery and reduce dialysis dependency, offering a beacon of hope for those affected by severe trauma and infection.

Dr. Andriy Batchinsky, principal investigator at AREVA, emphasized the study's potential impact, noting its capacity to save lives by addressing infection- and trauma-related organ failures. The Geneva Foundation will support the research administratively, ensuring the program's success at the AREVA Institute in San Antonio, Texas.

SeaStar Medical's SCD therapy has already shown promise in treating pediatric acute kidney injury (AKI), with clinical trials demonstrating significant reductions in mortality and dialysis duration. The ongoing study for adult AKI treatment further underscores the therapy's broad applicability, offering hope for patients with limited treatment options.

This collaboration represents a significant step forward in medical research, with the potential to transform the treatment landscape for severe burns and related conditions. The DoD's investment in this study underscores the importance of innovative therapies in improving survival rates and recovery outcomes for critically injured individuals.